These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1739178)

  • 21. Palliation of gastric outlet obstruction and proximal small bowel obstruction with self-expandable metal stents: a single center series.
    Mosler P; Mergener KD; Brandabur JJ; Schembre DB; Kozarek RA
    J Clin Gastroenterol; 2005 Feb; 39(2):124-8. PubMed ID: 15681907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of octreotide in malignant bowel obstruction.
    Krammer LM
    Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
    [No Abstract]   [Full Text] [Related]  

  • 23. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
    J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a safe site for percutaneous endoscopic gastrostomy placement in patients with marked bowel distension: may octreotide have a role?
    Sartori S; Trevisani L; Nielsen I; Tassinari D; Righini E
    Endoscopy; 1994 Oct; 26(8):710-1. PubMed ID: 7859687
    [No Abstract]   [Full Text] [Related]  

  • 25. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
    Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
    Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H
    Minoura T; Takeuchi M; Morita T; Kawakami K
    J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
    Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
    Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
    [No Abstract]   [Full Text] [Related]  

  • 29. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
    Mercadante S
    J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of external biliary, pancreatic and intestinal fistulas with a somatostatin analog.
    Kocak S; Bumin C; Karayalcin K; Alacayir I; Aribal D
    Dig Dis; 1994; 12(1):62-8. PubMed ID: 8200125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis.
    Mangili G; Aletti G; Frigerio L; Franchi M; Panacci N; Viganò R; DE Marzi P; Zanetto F; Ferrari A
    Int J Gynecol Cancer; 2005; 15(5):830-5. PubMed ID: 16174232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C; Zulian GB
    Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
    Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
    Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
    Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and treatment of acute intestinal obstruction due to gall-stone].
    Popov IuP; Eremeev VA; Skopin MS; Khasan ASh
    Khirurgiia (Mosk); 2006; (1):49-52. PubMed ID: 16482059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obstructing phytobezoar arising from proximal jejunal diverticulum.
    Lough E; Richmond B; Maxwell D; Hayes JD
    Am J Surg; 2008 Jan; 195(1):106-7. PubMed ID: 18082550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruptured jejunal diverticulum due to a single-band small bowel obstruction.
    Durai R; Sinha A; Khan M; Hoque H; Kerwat R
    ScientificWorldJournal; 2008 Sep; 8():934-40. PubMed ID: 18836661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G; Rousselot H; Toussaint-Martel S; Mayer F; Terrebonne E; François E; Brixi H; Nguyen T; Bourdeix I; Bisot-Locard S; Zelek L;
    Bull Cancer; 2012 Feb; 99(2):E1-9. PubMed ID: 22265994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of sandostatin in malignant bowel obstruction].
    Li J; Jing ML; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):479-81. PubMed ID: 17851794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.